Key facts
- It has raised $169.6M across 2 recorded rounds; the latest was Later Stage VC ($75.0M) in Nov 2020.
- Notable investors include Alumni Ventures, US National Science Foundation, Gates Foundation, MassVentures, Liebenthal Ventures — 22 tracked in total.
- Status: Privately Held (backing).
Leadership
- Ajikumar "Aji" ParayilFounder & Chief Executive Officer
- Christine SantosChief Technology Officer
- Julio Ruiz CalderonChief Financial Officer
- Frederik BjoerndalSenior Vice President, Corporate Affairs and Marketing
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for Manus
Funding rounds
2 roundsAbout Manus
Developer of a fermentation technology designed to recreate plant processes in microorganisms to produce natural ingredients through fermentation. The company's technology helps in manufacturing complex and bioactive natural products such as flavors, fragrances, food ingredients, bio-pesticides, and pharmaceuticals, enabling businesses to make affordable and sustainable products.
- Industry
- Biotech
- Sector
- Materials and Resources
- HQ
- Waltham, MA, United States
- Founded
- 2011
- Employees
- 164
- Website
- manusbio.com/
- Ownership
- Privately Held (backing)
Manus doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Manus shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Manus in its N-PORT filings yet. We sweep new filings monthly.